



(12) **United States Patent**  
**Essack et al.**

(10) **Patent No.:** **US 9,655,905 B2**  
(45) **Date of Patent:** **May 23, 2017**

(54) **TREATMENT OF SICKLE CELL DISEASE**

(75) Inventors: **Magbubah Essack**, Thuwal (SA);  
**Vladimir Bajic**, Thuwal (SA);  
**Aleksandar Radovanovic**, Thuwal  
(SA)

5,756,353 A 5/1998 Debs  
5,780,045 A 7/1998 McQuinn et al.  
5,792,451 A 8/1998 Sarubbi et al.  
5,804,212 A 9/1998 Illum  
6,613,308 B2 9/2003 Bartus et al.  
6,737,514 B1 5/2004 Wang et al.  
2007/0185045 A1 8/2007 Ratcliffe

(73) Assignee: **KING ABDULLAH UNIVERSITY  
OF SCIENCE AND TECHNOLOGY**,  
Thuwal (SA)

**FOREIGN PATENT DOCUMENTS**

WO WO-2004106325 A1 12/2004

(\* ) Notice: Subject to any disclaimer, the term of this  
patent is extended or adjusted under 35  
U.S.C. 154(b) by 0 days.

**OTHER PUBLICATIONS**

(21) Appl. No.: **14/345,206**

Charache et al., "Treatment of sickle cell anemia with 5-azacytidine results in increase fetal hemoglobin production and is associated with nonrandom hypomethylation of DNA around the  $\gamma$ - $\alpha$ - $\beta$ -globin gene complex", The Proceeding of the National Academy of Sciences of the USA, vol. 80, No. 15, pp. 4842-4846 (1983).  
Fibach et al., "Enhanced Fetal Hemoglobin Production by Phenylacetate and 4-Phenylbutyrate in Erythroid Precursors Derived From Normal Donors and Patients With Sickle Cell and  $\beta$ -Thalassemia", Blood, vol. 82, No. 7, pp. 2203-2209 (1993).  
Chokchaisiri et al., "Labdane diterpenes from the aerial parts of Curcuma comosa enhance fetal hemoglobin production in an erythroid cell line", Journal of Natural Products, Apr. 23, 2010, vol. 73, No. 4, pp. 724-728.  
Cokic et al., "Hydroxyurea induces fetal hemoglobin by the nitric oxide-dependent activation of soluble guanylyl cyclase", J Clin Invest, 2003, vol. 111, pp. 231-239.  
Olmes et al., "Improvement in hemolysis and pulmonary arterial systolic pressure in adult patients with sickle cell disease during treatment with hydroxyurea" *Am J Hematol*, Aug. 2009, vol. 84, No. 8, pp. 530-532.

(22) PCT Filed: **Sep. 13, 2012**

(86) PCT No.: **PCT/IB2012/002887**  
§ 371 (c)(1),  
(2), (4) Date: **Jun. 23, 2014**

(87) PCT Pub. No.: **WO2013/057592**  
PCT Pub. Date: **Apr. 25, 2013**

(65) **Prior Publication Data**

US 2014/0356458 A1 Dec. 4, 2014

**Related U.S. Application Data**

(60) Provisional application No. 61/534,449, filed on Sep. 14, 2011.

(51) **Int. Cl.**

**A61K 31/00** (2006.01)  
**A61K 31/47** (2006.01)  
**A61K 31/551** (2006.01)  
**A61K 31/341** (2006.01)  
**A61K 45/06** (2006.01)  
**A61K 31/365** (2006.01)  
**A61K 31/55** (2006.01)  
**A61K 31/472** (2006.01)

Brawley et al., "National Institutes of Health Consensus Development Conference Statement: Hydroxyurea Treatment for Sickle Cell Disease", *Ann Intern Med*, Jun. 17, 2008, vol. 148, No. 12., pp. 932-938.  
Haynes et al., "Hydroxyurea attenuates activated neutrophil-mediated sickle erythrocyte membrane phosphatidylserine exposure and adhesion to pulmonary vascular endothelium", American Journal of Physiology — Heart and Circulatory Physiology, Jan. 1, 2008, vol. 294, No. H379-H385.  
Abraham et al., "Asymmetric synthesis of N,O,O,O-tetra-acetyl d-lyxo-phytosphingosine, jaspine B (pachastrissamine), 2-epi-jaspine B, and deoxoprosophylline via lithium amide conjugate addition", *Org. Biomol. Chem.*, 6:1665-1673, 2008.  
Arita et al., "Rho kinase inhibition by fasudil ameliorates diabetes-induced microvascular damage", *Diabetes*, 58:215-226, 2009.  
Barabino et al., "Sickle cell biomechanics", *Annu. Rev. Biomed. Eng.*, 12:345-367, 2010.

(Continued)

(52) **U.S. Cl.**

CPC ..... **A61K 31/551** (2013.01); **A61K 31/341**  
(2013.01); **A61K 31/365** (2013.01); **A61K**  
**45/06** (2013.01); **A61K 31/472** (2013.01);  
**A61K 31/55** (2013.01)

(58) **Field of Classification Search**

CPC .. **A61K 31/47**; **A61K 31/472**; **A61K 31/5513**;  
**A61K 31/55**  
USPC ..... **514/49**, **211.01**, **307**  
See application file for complete search history.

*Primary Examiner* — Kevin E Weddington

(74) *Attorney, Agent, or Firm* — Smith, Gambrell &  
Russell, LLP

(56) **References Cited**

**U.S. PATENT DOCUMENTS**

5,399,363 A 3/1995 Liversidge et al.  
5,466,468 A 11/1995 Schneider et al.  
5,543,158 A 8/1996 Gref et al.  
5,580,579 A 12/1996 Ruddy et al.  
5,641,515 A 6/1997 Ramtoola  
5,725,871 A 3/1998 Illum

(57) **ABSTRACT**

The present invention includes embodiments for treatment and/or prevention of sickle cell disease that employ Hydroxyfasudil or Isocoronarin D alone or either in conjunction with each other or an inducer of HbF production. The compounds may act synergistically, and the compounds employed circumvent the side effects seen with Hydroxyurea.

**8 Claims, No Drawings**